Mufg Americas Holdings Has Boosted Hess (HES) Position; PROTEON THERAPEUTICS (PRTO)’s Sentiment Is 1.14

February 15, 2018 - By Vivian Currie

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $37.71 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Mufg Americas Holdings Corp increased Hess Corp (HES) stake by 1660.67% reported in 2017Q3 SEC filing. Mufg Americas Holdings Corp acquired 123,670 shares as Hess Corp (HES)’s stock declined 5.45%. The Mufg Americas Holdings Corp holds 131,117 shares with $6.15 million value, up from 7,447 last quarter. Hess Corp now has $14.36 billion valuation. The stock decreased 0.40% or $0.18 during the last trading session, reaching $45.19. About 2.33M shares traded. Hess Corporation (NYSE:HES) has declined 14.55% since February 15, 2017 and is downtrending. It has underperformed by 31.25% the S&P500.

Ratings analysis reveals 50% of Proteon Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Proteon Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $3.0 while the high is $19.0. The stock’s average target of $10.75 is 402.34% above today’s ($2.14) share price. PRTO was included in 6 notes of analysts from September 22, 2016. Raymond James upgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Wednesday, October 26 to “Strong Buy” rating. The firm earned “Buy” rating on Thursday, September 22 by H.C. Wainwright. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) has “Mkt Perform” rating given on Wednesday, December 14 by JMP Securities. Stifel Nicolaus downgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Wednesday, December 14 to “Hold” rating. Robert W. Baird downgraded Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Tuesday, December 13 to “Neutral” rating. Maxim Group initiated Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Thursday, November 10. Maxim Group has “Buy” rating and $19.0 target.

The stock decreased 2.73% or $0.06 during the last trading session, reaching $2.14. About 18,778 shares traded. Proteon Therapeutics, Inc. (PRTO) has declined 80.63% since February 15, 2017 and is downtrending. It has underperformed by 97.33% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on March, 15. They expect $-0.43 EPS, down 2.38% or $0.01 from last year’s $-0.42 per share. After $-1.08 actual EPS reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -60.19% EPS growth.

Deer Vii & Co. Ltd. holds 10.12% of its portfolio in Proteon Therapeutics, Inc. for 315,101 shares. Abingworth Llp owns 2.02 million shares or 2.72% of their US portfolio. Moreover, Mpm Asset Management Llc has 0.96% invested in the company for 983,381 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.24% in the stock. Deerfield Management Co, a New York-based fund reported 1.22 million shares.

Since January 1, 0001, it had 1 insider purchase, and 0 sales for $22,560 activity.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.12, from 1 in 2017Q2. It dived, as 43 investors sold HES shares while 162 reduced holdings. 48 funds opened positions while 133 raised stakes. 254.48 million shares or 1.67% more from 250.30 million shares in 2017Q2 were reported. The New York-based Oppenheimer & Com has invested 0.01% in Hess Corporation (NYSE:HES). Aviva Public Limited Co, United Kingdom-based fund reported 476,910 shares. Indexiq Advsr Ltd Liability Corporation invested 0% of its portfolio in Hess Corporation (NYSE:HES). Advsrs Asset Management has invested 0.01% in Hess Corporation (NYSE:HES). Arizona State Retirement Systems holds 0.06% in Hess Corporation (NYSE:HES) or 106,692 shares. Earnest Prtn Limited Liability Corporation, Georgia-based fund reported 40,303 shares. Texas Yale invested in 0.03% or 7,600 shares. Raymond James Financial Advisors Incorporated stated it has 0.01% in Hess Corporation (NYSE:HES). Exane Derivatives accumulated 2,141 shares. State Teachers Retirement reported 0.05% stake. Old Mutual Customised Solutions (Proprietary) Ltd accumulated 0.11% or 17,227 shares. M&T Financial Bank holds 24,321 shares or 0.01% of its portfolio. 82,250 were accumulated by Reaves W H And. Moreover, Nomura Asset Mngmt Ltd has 0.03% invested in Hess Corporation (NYSE:HES). 59,997 are held by Citadel Advisors Ltd Co.

Among 22 analysts covering Hess Corp. (NYSE:HES), 9 have Buy rating, 2 Sell and 11 Hold. Therefore 41% are positive. Hess Corp. had 62 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Wednesday, July 22. The stock of Hess Corporation (NYSE:HES) has “Hold” rating given on Tuesday, July 18 by Cowen & Co. BMO Capital Markets maintained the stock with “Hold” rating in Friday, July 28 report. JP Morgan downgraded Hess Corporation (NYSE:HES) on Thursday, September 14 to “Neutral” rating. The firm earned “Hold” rating on Thursday, September 14 by J.P. Morgan. Oppenheimer downgraded Hess Corporation (NYSE:HES) on Tuesday, November 17 to “Perform” rating. On Tuesday, January 23 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Barclays Capital with “Equal Weight” on Tuesday, January 12. Morgan Stanley initiated the shares of HES in report on Tuesday, January 12 with “Equal-Weight” rating. On Tuesday, April 11 the stock rating was upgraded by Wolfe Research to “Outperform”.

Since August 24, 2017, it had 0 insider buys, and 9 selling transactions for $5.74 million activity. Shares for $85,261 were sold by Lowery-Yilmaz Barbara J. The insider Hill Gregory P. sold 6,312 shares worth $280,442. Another trade for 1,926 shares valued at $85,572 was made by Truelove Brian D. on Thursday, February 8. On Thursday, February 8 Turner Michael R sold $85,039 worth of Hess Corporation (NYSE:HES) or 1,914 shares. $4.15M worth of stock was sold by HESS JOHN B on Thursday, February 8. Goodell Timothy B. had sold 4,567 shares worth $202,075. $150,262 worth of stock was sold by RIELLY JOHN P on Thursday, February 8.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Currie

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts